ASLAN Gains Global Rights to Immuno-Oncology Candidate from A*STAR
publication date: Sep 1, 2016
ASLAN Pharma of Singapore in-licensed global rights to a novel immuno-oncology antibody that targets RON (Recepteur d’Origine Nantais) from Singapore’s A*STAR (Agency for Science, Technology and Research). An overexpression of RON, a tyrosine kinase, is associated with increased tumor metastasis. A*STAR’s p53 Laboratory will continue to be responsible for the preclinical development of the antibody, while ASLAN will design an innovative clinical development plan. The two entities have formed a three-year research collaboration to advance development of the drug candidate. More details....
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.